Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib First-in-Human Study of EOS100850 (Inupadenant) As a Single Agent and in Combination with Pembrolizumab And/or Chemotherapy in Participants with Advanced Cancers

NCT03873883 is registered in ClinicalTrials.gov with iTeos Therapeutics as lead sponsor.

NCT NCT03873883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03873883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib First-in-Human Study of EOS100850 (Inupadenant) As a Single Agent and in Combination with Pembrolizumab And/or Chemotherapy in Participants with Advanced Cancers
Lead sponsor
iTeos Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
February 5, 2019
Completion date
May 28, 2024
Enrollment
119 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult